Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
By Zhaowei Chen, Jijia Hu, Zongwei Zhang, Sha-sha Jiang, Shoumeng Han, D. Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang. medRxiv, 2020
863 citations recorded by the source corpus.
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31) compared with the control group (54.8%, 17 of 31). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/9a4820e2f904e7ee73a4a137176ef00fd57c57a8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (2022, background): “progression on CT scan), clinical improvement, failure of virologic clearance (PCR), and adverse events (both) [11, 12] (Table 1).”
- Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19 (2020, background): “A total of 368 patients met inclusion criteria and were assigned to one of three cohorts based on medication exposure: (1) HC-treated; (2) HC- and AZ-treated; or (3) HC-untreated.”
- Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, neutral): “At the time of writing this review, seven articles are reporting clinical data (observational studies or clinical trials), with either positive (n=4) [189] [190] [191] [192] or negative (n=5) results [193] [194] [195] [196] , but no definitive conclusions can currently be drawn because of major bias”
- Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study (2020, background): “Finally, another Chinese study conducted in 62 COVID-19 patients showed significantly shortened body temperature recovery time, cough remission time and larger proportion of improved pneumonia as assessed by CT scan in patients treated with 400mg per day during five days (N=31) than in controls (N= ”